Payment overview · 2025
General Payments
$4,599.20
168 reported records · 30 companies
Healthcare provider profile · identity verified
Rakesh Passi, M.D.,
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · EAST BRUNSWICK, NJ · NPI 1275550915
Verified facts
What the public records show
CMS Open Payments records show Rakesh Passi, M.D., received $4,599.20 in general payments during 2025 across 168 reported records.
Boston Scientific Corporation accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 242 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 691 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nexlizet by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 257 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 260 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 691 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYNDAMAX as an associated drug or biological on 1880 records involving 1527 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vyndamax by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $850.56 | 18.5% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $849.43 | 18.5% | 13 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $438.79 | 9.5% | 7 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $330.19 | 7.2% | 22 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $323.76 | 7.0% | 21 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $272.84 | 5.9% | 5 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $165.90 | 3.6% | 10 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $143.34 | 3.1% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $114.16 | 2.5% | 7 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $108.59 | 2.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $104.12 | 2.3% | 6 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$83.33 | 1.8% | 4 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $82.49 | 1.8% | 4 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $81.12 | 1.8% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $78.36 | 1.7% | 3 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $74.02 | 1.6% | 4 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $65.48 | 1.4% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $63.55 | 1.4% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $62.40 | 1.4% | 4 | 2025 |
| Vital Connect, Inc | Unresolved — no canonical attribution shown | $49.49 | 1.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.16 | 1.0% | 3 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $35.13 | 0.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $34.36 | 0.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.30 | 0.7% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $20.88 | 0.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.66 | 0.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.00 | 0.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.52 | 0.4% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.63 | 0.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.64 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,599.20 | 168 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $620.70 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $456.43 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $323.76 | 21 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $277.02 | 6 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $272.84 | 5 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $223.12 | 13 | 2025 |
Source payment records
|
|||||
| Wolverine Coronary Cutting Balloon Normalized: wolverine coronary cutting balloon |
Device | Boston Scientific Corporation | $219.11 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $165.90 | 10 | 2025 |
Source payment records
|
|||||
| MAMBA Normalized: mamba |
Device | Boston Scientific Corporation | $147.33 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $143.34 | 10 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $126.07 | 10 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $124.94 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $114.16 | 7 | 2025 |
Source payment records
|
|||||
| Guidezilla Normalized: guidezilla |
Device | Boston Scientific Corporation | $112.97 | 2 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $108.59 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $104.12 | 6 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $82.49 | 4 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $81.12 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $78.36 | 3 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $74.02 | 4 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $65.48 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $63.55 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $62.40 | 4 | 2025 |
Source payment records
|
|||||
| Comet Normalized: comet |
Device | Boston Scientific Corporation | $56.22 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $55.95 | 3 | 2025 |
Source payment records
|
|||||
| VITALPATCH RTM Normalized: vitalpatch rtm |
Device | Vital Connect, Inc | $49.49 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $46.16 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $44.40 | 2 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $35.13 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $34.36 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31.30 | 2 | 2025 |
Source payment records
|
|||||
| Hornet 10 Normalized: hornet 10 |
Device | Boston Scientific Corporation | $27.56 | 1 | 2025 |
Source payment records
|
|||||
| FFRANGIO Normalized: ffrangio |
Device | Medtronic, Inc. | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| ROTAPRO Normalized: rotapro |
Device | Boston Scientific Corporation | $10.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 691 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 242 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 197 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
167 | 70 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
242 | 69 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
197 | 63 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
691 | 172 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
197 | 63 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
74 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
89 | 20 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
257 | 69 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
260 | 64 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
691 | 172 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | VYNDAMAX open payments reported associated product |
CMS Open Payments — General Payments 1880 supporting records · 1527 recipient NPIs · example record 1228795749 |
Vyndamax · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1665 | 547 |
| Metoprolol Succinate | Metoprolol Succinate | 1352 | 482 |
| Amlodipine Besylate | Amlodipine Besylate | 1109 | 405 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1070 | 341 |
| Metoprolol Tartrate | Metoprolol Tartrate | 859 | 285 |
| Eliquis | Apixaban | 691 | 172 |
| Furosemide | Furosemide | 662 | 216 |
| Metformin Hcl | Metformin Hcl | 635 | 208 |
| Losartan Potassium | Losartan Potassium | 632 | 206 |
| Clopidogrel | Clopidogrel Bisulfate | 484 | 178 |
| Levothyroxine Sodium | Levothyroxine Sodium | 478 | 148 |
| Carvedilol | Carvedilol | 475 | 141 |
| Xarelto | Rivaroxaban | 396 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 392 | 151 |
| Lisinopril | Lisinopril | 388 | 134 |
| Nifedipine Er | Nifedipine | 368 | 131 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 351 | 135 |
| Hydrochlorothiazide | Hydrochlorothiazide | 324 | 104 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 266 | 89 |
| Doxazosin Mesylate | Doxazosin Mesylate | 261 | 84 |
| Ozempic | Semaglutide | 260 | 64 |
| Entresto | Sacubitril/Valsartan | 257 | 69 |
| Hydralazine Hcl | Hydralazine Hcl | 247 | 81 |
| Farxiga | Dapagliflozin Propanediol | 242 | 69 |
| Allopurinol | Allopurinol | 236 | 69 |
| Omeprazole | Omeprazole | 218 | 74 |
| Simvastatin | Simvastatin | 217 | 65 |
| Ezetimibe | Ezetimibe | 211 | 87 |
| Warfarin Sodium | Warfarin Sodium | 209 | 38 |
| Jardiance | Empagliflozin | 197 | 63 |
| Alprazolam | Alprazolam | 180 | 68 |
| Brilinta | Ticagrelor | 167 | 70 |
| Gabapentin | Gabapentin | 161 | 62 |
| Atenolol | Atenolol | 155 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 43 |
| Clonidine Hcl | Clonidine Hcl | 141 | 53 |
| Amiodarone Hcl | Amiodarone Hcl | 140 | 56 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 139 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 59 |
| Nitroglycerin | Nitroglycerin | 135 | 90 |
| Pravastatin Sodium | Pravastatin Sodium | 128 | 43 |
| Potassium Chloride | Potassium Chloride | 117 | 38 |
| Spironolactone | Spironolactone | 116 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 36 |
| Glimepiride | Glimepiride | 108 | 36 |
| Montelukast Sodium | Montelukast Sodium | 107 | 35 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 99 | 32 |
| Famotidine | Famotidine | 98 | 28 |
| Meloxicam | Meloxicam | 97 | 53 |
| Metformin Hcl Er | Metformin Hcl | 95 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 32 |
| Trulicity | Dulaglutide | 89 | 20 |
| Januvia | Sitagliptin Phosphate | 85 | 20 |
| Digoxin | Digoxin | 79 | 23 |
| Repatha Sureclick | Evolocumab | 77 | 14 |
| Trazodone Hcl | Trazodone Hcl | 75 | 29 |
| Mounjaro | Tirzepatide | 74 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 74 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 73 | 22 |
| Fenofibrate | Fenofibrate | 72 | 30 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 72 | 20 |
| Multaq | Dronedarone Hcl | 70 | 15 |
| Valsartan | Valsartan | 70 | 29 |
| Synthroid | Levothyroxine Sodium | 66 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 65 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 37 |
| Irbesartan | Irbesartan | 63 | 24 |
| Meclizine Hcl | Meclizine Hcl | 62 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 21 |
| Sotalol | Sotalol Hcl | 58 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 58 | 28 |
| Enalapril Maleate | Enalapril Maleate | 56 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 56 | 20 |
| Sertraline Hcl | Sertraline Hcl | 56 | 19 |
| Vascepa | Icosapent Ethyl | 53 | 17 |
| Metolazone | Metolazone | 52 | 23 |
| Alendronate Sodium | Alendronate Sodium | 51 | 17 |
| Gemfibrozil | Gemfibrozil | 51 | 15 |
| Donepezil Hcl | Donepezil Hcl | 48 | 16 |
| Mirtazapine | Mirtazapine | 47 | 17 |
| Telmisartan | Telmisartan | 45 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 37 |
| Cilostazol | Cilostazol | 42 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 14 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 41 | suppressed |
| Torsemide | Torsemide | 41 | 14 |
| Amoxicillin | Amoxicillin | 40 | 19 |
| Memantine Hcl | Memantine Hcl | 39 | 15 |
| Ramipril | Ramipril | 39 | 13 |
| Azithromycin | Azithromycin | 38 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 13 |
| Linzess | Linaclotide | 36 | 15 |
| Methylprednisolone | Methylprednisolone | 35 | 29 |
| Promethazine Hcl | Promethazine Hcl | 35 | 27 |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Finasteride | Finasteride | 34 | 16 |
| Labetalol Hcl | Labetalol Hcl | 34 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 20 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 32 | suppressed |
| Topiramate | Topiramate | 32 | 11 |
| Nitroglycerin Patch | Nitroglycerin | 31 | suppressed |
| Repaglinide | Repaglinide | 31 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 12 |
| Praluent Pen | Alirocumab | 29 | suppressed |
| Glipizide | Glipizide | 28 | 14 |
| Lorazepam | Lorazepam | 28 | suppressed |
| Prednisone | Prednisone | 28 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | 11 |
| Glipizide Er | Glipizide | 26 | suppressed |
| Restasis | Cyclosporine | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | 12 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Clonidine | Clonidine | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | 15 |
| Diazepam | Diazepam | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Xiidra | Lifitegrast | 19 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Eplerenone | Eplerenone | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Niacin Er | Niacin | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Vyndamax | Tafamidis | 15 | suppressed |
| Benicar | Olmesartan Medoxomil | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Corlanor | Ivabradine Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 12 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Crestor | Rosuvastatin Calcium | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Letairis | Ambrisentan | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,599.20 · 168 records | Boston Scientific Corporation | AIRSUPRA, AVVIGO Guidance System, Attruby, BIOMONITOR, BREZTRI, Barostim Neo System, CAMZYOS, CARDIOMEMS, Cologuard Collection Kit, Comet, ELIQUIS, FARXIGA, FFRANGIO, FFRct, FUROSCIX, Guidezilla, Hillrom - Carnation Ambulatory Monitor, Hornet 10, INSPIRE, JARDIANCE, Kerendia, Korlym, LEQVIO, LOKELMA, LifeVest, MAMBA, MOUNJARO, NEXLETOL, ONPATTRO, REPATHA, ROTAPRO, SYMPLICITY G3, UPTRAVI, VERQUVO, VITALPATCH RTM, Veozah, Wegovy, Wolverine Coronary Cutting Balloon, XIFAXAN, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error